Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.
Founded in 2010 by the neuropsychopharmacologist Professor David Nutt, independent research charity Drug Science is the leading organisation of its kind in the UK — and has built a renowned international reputation as thought leaders, particularly around the study of cannabis and psychedelics.
The charity is now launching Drug Science Consultancy, to provide research advice and consultancy services to businesses, governments and other stakeholders in all drug-related areas.
CEO of Drug Science, Dr Anne Katrin Schlag, stated: “We are often asked to share our expertise and are excited to now have our own consultancy to develop this stream.
“Drug Science Consultancy will allow us to work closely together with clients who are keen to develop, conduct, and analyse their own high-quality scientific research — which is what we love doing.”
In line with the charity’s ethos, Drug Science Consultancy is committed to providing the highest quality scientific evidence, research advice and consultancy services. Importantly, all profits will be returned to the charity to support its charitable objectives.
Drug Science Consultancy has established partnerships with the leading academic institutions in the UK as well as many global experts, and will also work together with a trusted national group of Contract Research Organisations.
Through its consultancy, Drug Science will share its wealth of knowledge to support clients throughout the whole research ecosystem: from project development and management, conducting both quantitative and qualitative studies, over Real World evidence and clinical trial development as well as communication and marketing.
Drug Science’s Chief Research Officer, Professor Michael Lynskey, added: “Setting up research involving scheduled drugs can be a daunting prospect,” says
“Especially if you haven’t submitted a study for regulatory approvals before. We can ensure that clients’ great ideas do not fall at the first hurdle but rather that they are presented and organised in a way that offers the best chance of success.”
“By sharing our knowledge in this way we hope to benefit many other organisations,” said Professor David Nutt, chairman of Drug Science.
“And also to continue building the scientific evidence base about drugs, specifically cannabis and psychedelics, which are showing such tremendous promise as medicines. Because that will benefit us all.”
More information can be downloaded here.
